Post

New in @jamanetworkopen.com: Phase 2 results for Dengue-mAb show the first proof of concept for an antiviral as a treatment for confirmed dengue patients seeking medical care. At 5–7mg/kg, it rapidly cut viremia and fever, with no related serious AEs. 📄 Study: jamanetwork.com/journals/jam... 1/2

jamanetwork.comSafety and Preliminary Efficacy of Dengue Monoclonal Antibody in Adult PatientsThis randomized clinical trial examines dengue monoclonal antibody (Dengue-mAb) as a potential therapeutic option for adults infected with dengue virus in India.

Drugs for Neglected Diseases initiative (DNDi)

@dndi.org

27 Aug

This is the science behind the Phase 3 trial now running in 🇧🇷 🇲🇾 🇹🇭. Developed by @seruminstindia.bsky.social, financed by DG HERA @euinemergencies.ec.europa.eu, led by DNDi in partnership with @afd-france.bsky.social. 📰 Background: dndi.org/press-releas... #Dengue #GlobalHealth 2/2

dndi.orgBrazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment developed by Serum Institute of IndiaFollowing a licensing agreement signed between the Serum Institute of India (SII) and DNDi, a Phase III clinical trial is expected to begin early next year, with the aim of developing a safe, effectiv...

Drugs for Neglected Diseases initiative (DNDi)

@dndi.org

Preparations for the Phase III trials are underway, with the trials set to begin in early 2027. Watch this space! 3/3

28/8/26, 9:28 am0 reposts0 likes

No replies yet.